micro-community-banner
Profile Image
  • Saved
The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis - PubMed

The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36769420/

(1) Background: Recent advances in the pharmacological treatment of obesity with glucagon-like peptide-1 receptor agonists (GLP-1 RA) highlight the potential to target excess body weight to improve blood pressure (BP)....



Conclusions: A clinically significant reduction in BP was evident following semaglutide treatment in normotensive populations without diabetes. The effect of semaglutide in those with obesity and hypertension is as yet undetermined. Targeting excess body weight may be a novel therapeutic strategy for these

Profile Image
  • Saved
GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Source : https://academic.oup.com/jcem/advance-article-abstract/doi/10.1210/clinem/dgad076/7044761?redirectedFrom=fulltext&login=false

You do not currently have access to this article. GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled...



Conclusion: GLP-1RAs, precisely longer acting formulations, reduced ischemic cerebrovascular events in T2DM. Observed benefits were significantly higher in patients with shorter T2DM duration and higher eGFR.

Profile Image
  • Saved
Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes

Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes

Source : https://journals.lww.com/cardiovascularendocrinology/Fulltext/2023/03000/Prioritizing_obesity_treatment__expanding_the_role.7.aspx

s for obesity, which are associated with numerous health benefits. Modest weight reductions of 5-10% improve cardiovascular risk factors, with greater weight loss bringing about greater benefits. Anti-obesity medications can...



Relevance: There are several treatment options for obesity, which are associated with numerous health benefits. Modest weight reductions of 5–10% improve cardiovascular risk factors, with greater weight loss bringing about greater benefits. Anti-obesity medications can support weight reduction when lifestyle modifications alone are...

Profile Image
  • Saved
Treatment with semaglutide, a GLP-1 receptor agonist, improves extracellular matrix remodeling in the pancreatic islet of diet-induced obese mice

Treatment with semaglutide, a GLP-1 receptor agonist, improves extracellular matrix remodeling in the pancreatic islet of diet-induced obese mice

Source : https://www.sciencedirect.com/science/article/abs/pii/S0024320523001364?via=ihub

Available online 14 February 2023, 121502 Author links open overlay panel Luiz E. Macedo Cardoso , Thatiany Souza Marinho , Fabiane Ferreira Martins , Marcia Barbosa Aguila , Carlos A....



Significance: Semaglutide improved the turnover of islet heparan sulfate proteoglycans, hyaluronan, chondroitin sulfate proteoglycans, and collagens in the islet ECM. Such changes should contribute to restoring a healthy islet functional milieu and should reduce the formation of cell-damaging amyloid deposits. Our findings also provide...

Profile Image
  • Saved
Once-weekly semaglutide use in patients with type 2 diabetes: real-world data from the SURE Italy observational study - PubMed

Once-weekly semaglutide use in patients with type 2 diabetes: real-world data from the SURE Italy observational study - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36789682/

The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....



Conclusions: In routine clinical practice in Italy, patients with T2D treated with OW semaglutide for 30 weeks achieved clinically significant improvements in HbA1c , BW and other outcomes. This article is protected by copyright. All rights reserved.

Profile Image